Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab - Sorrentino, Dario; Marino, Marco; Dassopoulos, Themistocles; Zarifi, Dimitra; Del Bianco, Tiziana (PloS one, 2015)
Keywords: Adult; Analysis; Antibodies; Biomarkers - metabolism; C-Reactive Protein - metabolism; Care and treatment; Case-Control Studies; Colon; Colonoscopy; Complications and side effects; Crohn Disease - drug therapy; Crohn Disease - prevention & control; Crohn Disease - surgery; Crohn's disease; Crohns disease; Dosage and administration; Dose-Response Relationship, Drug; Drug dosages; Drug therapy; Endoscopy; Enrollments; Feces - chemistry; Female; Follow-Up Studies; Gastroenterology; Humans; Immunoglobulins; Immunotherapy; Inflammation; Inflammatory bowel disease; Infliximab; Infliximab - immunology; Infliximab - pharmacokinetics; Infliximab - therapeutic use; Leukocyte L1 Antigen Complex - metabolism; Male; Medicine; Middle Aged; Monoclonal antibodies; Mucosa; Patients; Pharmacokinetics; Pharmacology; Postoperative Period; Prevention; Prognosis; Recurrence; Recurrence (Disease); Remission; Risk factors; Side effects; Surgery; Systematic review; Therapy; Tumor necrosis factor-TNF; Tumor necrosis factor-α; United States; United States--US; Italy; Virginia